Business

Cramer's Lightning Round: Vir and GlaxoSmithKline ‘May Have Something' That Could Fight Omicron

Source: CNBC
  • “Mad Money” host Jim Cramer rings the lightning round bell on Vir Biotechnology, Enbridge, On Semiconductor and Robinhood.

Vir Biotechnology (VIR): "[George Scangos] runs that company. And I have to tell you he's part of a GlaxoSmithKline [alliance]. And I spend a lot of time talking to GlaxoSmithKline. They may have something that could be very, very good against omicron. It's very early, very early. But I like it. I think you should own the stock."

Enbridge (ENB): "That stock has just been in a house of pain. However, it does yield 7%. That's [CEO] Al Monaco. They've got a great long term business. I don't understand why it's going down, other than being brought down by the fact that oil suddenly went from $80 to $70 to $64. Buy Enbridge."

On Semiconductor (ON): "We've had [CEO] Hassane El-Khoury on multiple times. I think he's a genius. He put together Cypress with this. He's got the best automobile chips. He's got internet of things. That stock is a buy to me."

Robinhood (HOOD): "Here's the problem with Robinhood: They've got the wrong customer base. They have a great app. But remember when I had that young person come on and say, 'Why am I using Robinhood, because I'm tired of Candy Crush.' There's got to be more to it than that."

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Copyright CNBCs - CNBC
Contact Us